Bayer has launched Bayer Co.Lab AdVenture, a new platform for its Bayer Co.Lab global lifesciences incubator network, which aims to connect Venture Capital (VC) partners globally. Bayer Co.Lab AdVenture bridges tenants of high-potential biotech startups with leading VC firms, accelerating access to global financing and investment networks, thereby advancing the translation of early-stage ideas into impactful global solutions.

This advancement was introduced on the first anniversary of Bayer Co.Lab Shanghai, which also welcomed two additional Chinese biotech startups into its vibrant community. These milestones signify a pivotal moment in Bayer’s open innovation strategy and reinforce its commitment to deeply rooting in countries with a strong innovation footprint, while fostering global connections.

“Collaboration is essential to drive pharmaceutical innovation. With the introduction of Bayer Co.Lab AdVenture, we are partnering with leading venture capital firms to empower biotech start-ups by providing access to global financing and investment networks that accelerates their growth. We will continue to deepen collaboration with innovators and partners, driving transformative innovations to address global health challenges and improve outcomes for patients worldwide.”

The inaugural partners of Bayer Co.Lab AdVenture include Shanghai Industrial Investment Capital (SIIC), Legend Capital, IDG Capital and Bayland Capital. Drawing on deep investment expertise and strong local networks, these firms will support Bayer Co.Lab resident startups with strategic advice and curated investment opportunities.

At the anniversary event, Bayer Co.Lab Shanghai welcomed OTR Therapeutics and Nutshell Therapeutics as new start-up resident whose research and development (R&D) directions closely align with Bayer’s global strategic priorities, reflecting a shared commitment to innovative and high-potential treatment modalities that address high unmet medical needs.